Cargando…
Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non–Small Cell Lung Cancer: Updated Analysis of the RESET Study
PURPOSE: This study aimed to report the final analysis of time-on-treatment (TOT) and overall survival (OS) in patients with advanced-stage epidermal growth factor receptor (EGFR)+ non–small cell lung cancer (NSCLC) who received sequential afatinib and osimertinib and to compare the outcomes with ot...
Autores principales: | Kim, Taeyun, Jang, Tae Won, Choi, Chang Min, Kim, Mi-Hyun, Lee, Sung Yong, Chang, Yoon Soo, Lee, Kye Young, Kim, Seung Joon, Yang, Sei Hoon, Ryu, Jeong Seon, Lee, Jeong Eun, Lee, Shin Yup, Park, Chan Kwon, Lee, Sang Hoon, Jang, Seung Hun, Yoon, Seong Hoon, Oh, Hyung-Joo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582551/ https://www.ncbi.nlm.nih.gov/pubmed/37218139 http://dx.doi.org/10.4143/crt.2023.493 |
Ejemplares similares
-
Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea
por: Kim, Taeyun, et al.
Publicado: (2021) -
Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors
por: Kim, Jehun, et al.
Publicado: (2023) -
Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
por: Lee, Sung Yong, et al.
Publicado: (2021) -
Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022) -
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
por: Lee, Jang Ho, et al.
Publicado: (2023)